Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.

Trial Details

NCT ID
NCT05253131
Phase
PHASE2
Sponsor
University of Alabama at Birmingham
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Selumetinib + ZEN-3694 ± Durvalumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Inclusion Criteria AGE: ≥ 18 years of age Weight: \>30 kg Life expectancy of at least 12 weeks
  • Part A and B (Phase 1): Patients with histologically confirmed soft tissue or bone sarcoma of the following subtypes:
  • MFH/ undifferentiated pleomorphic sarcoma
  • Unclassified sarcoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →